{"id":61456,"date":"2024-02-28T07:41:49","date_gmt":"2024-02-28T07:41:49","guid":{"rendered":"https:\/\/medsname.com\/d-mine\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"d-mine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/d-mine\/","title":{"rendered":"D-mine"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is D-mine?<\/h3>\n
\n

D-mine<\/strong> obsahuje imipramine 25 mg<\/strong> from a WHO-GMP certified manufacturer (Sun Pharma) — the original tricyclic antidepressant<\/strong>, in continuous clinical use since 1959. Tertiary-amine TCA: serotonin and norepinephrine reuptake inhibition plus muscarinic, histamine H1<\/sub>, and alpha-1 antagonism (the source of side effects). Largely displaced by SSRIs for first-line depression but still used for: panick\u00e1 porucha<\/strong> (one of the most-evidenced TCAs for this), chronic neuropathic pain<\/strong> at low doses, and paediatric nocturnal enuresis<\/strong> (bedwetting) where it has FDA approval. Cardiac toxicity in overdose<\/strong> — baseline ECG before starting. Strong anticholinergic burden — not first-line in older adults.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<\/div>\n

Important — this is not a situational-anxiety medication.<\/strong> D-mine is a tricyclic antidepressant (TCA)<\/strong>, prescribed and titrated over weeks for major depressive disorder (MDD), panic disorder, paediatric nocturnal enuresis, and chronic pain syndromes<\/strong>. It is ne<\/strong> the right drug for acute, performance-related anxiety (flying, public speaking, exams) — for those use cases beta-blockers (propranolol), benzodiazepines, or hydroxyzine are clinically appropriate. If you do not have a diagnosed mood, anxiety, or psychiatric disorder, do not start this medication.<\/div>\n
FDA black-box warning — suicidality.<\/strong> All antidepressants carry an FDA black-box warning for increased risk of suicidal thinking and behaviour in children, adolescents, and young adults under 25, particularly during the first weeks of treatment or after dose changes. Family members and prescribers should monitor closely for worsening mood, agitation, or suicidal ideation in this age group.<\/div>\n

What Is D-mine?<\/h2>\n

D-mine is an oral tablet of imipramine hydrochloride 25 mg<\/strong> manufactured by Sun Pharma. Imipramine (US brand Tofranil<\/strong>) was synthesised in 1948 and identified as the first effective antidepressant in 1957 — the foundation of modern psychopharmacology. It is a tertiary-amine tricyclic antidepressant<\/strong> that inhibits serotonin and norepinephrine reuptake while also blocking muscarinic, histamine H1<\/sub>, and alpha-1 receptors. The serotonergic \/ noradrenergic actions drive efficacy; receptor blockade drives most of the side-effect burden.<\/p>\n

Schv\u00e1len\u00e9 indikace<\/h2>\n